Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia

被引：0
|
作者：
Vanover, Kimberly [1 ]
Correll, Christoph [1 ]
Weingart, Michal [1 ]
Saillard, Jelena [1 ]
Hossain, Shawn [1 ]
Glass, Steven [1 ]
Kozauer, Susan [1 ]
Satlin, Andrew [1 ]
Davis, Robert [1 ]
机构：
[1] Intracellular Therapies Inc, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2018年 / 43卷
关键词：
Schizophrenia Novel Treatment; Long-Term Safety; Antipsychotic;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
T184
引用
收藏
页码：S328 / S329
页数：2
相关论文
共 50 条
  • [31] LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
    Davis, Robert
    Dmitrienko, Alex
    Glass, Steven
    Kozauer, Susan
    Saillard, Jelena
    Weingart, Michal
    Satlin, Andrew
    Mates, Sharon
    Correll, Christoph
    Vanover, Kimberly
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S236 - S237
  • [32] Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
    Kimberly E. Vanover
    Robert E. Davis
    Yun Zhou
    Weiguo Ye
    James R. Brašić
    Lorena Gapasin
    Jelena Saillard
    Michal Weingart
    Robert E. Litman
    Sharon Mates
    Dean F. Wong
    Neuropsychopharmacology, 2019, 44 : 598 - 605
  • [33] MECHANISM OF ACTION OF ITI-007: A NOVEL THERAPY FOR THE TREATMENT OF SCHIZOPHRENIA AND RELATED PSYCHOSES
    Snyder, Gretchen L.
    Vanover, Kimberly
    Hendick, Joseph
    Yao, Wei
    Li, Peng
    Davis, Robert E.
    Wennogle, Lawrence P.
    Mates, Sharon
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S368 - S368
  • [34] Additional Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia
    Satlin, Andrew
    Vanover, Kimberly
    Durgam, Suresh
    Mates, Sharon
    Davis, Robert
    Correll, Christoph
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 493 - 494
  • [35] Efficacy of lumateperone (ITI-007) in improving global disease severity in patients with bipolar depression
    Kozauer, Susan
    Satlin, Andrew
    Durgam, Suresh
    Vanover, Kimberly E.
    Davis, Robert E.
    Huo, Jason
    Mates, Sharon
    Sachs, Gary S.
    BIPOLAR DISORDERS, 2020, 22 : 112 - 112
  • [36] Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
    Vanover, Kimberly E.
    Davis, Robert E.
    Zhou, Yun
    Ye, Weiguo
    Brasic, James R.
    Gapasin, Lorena
    Saillard, Jelena
    Weingart, Michal
    Litman, Robert E.
    Mates, Sharon
    Wong, Dean F.
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (03) : 598 - 605
  • [37] Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial
    Suppes, Trisha
    Durgam, Suresh
    Kozauer, Susan G.
    Chen, Richard
    Lakkis, Hassan D.
    Davis, Robert E.
    Satlin, Andrew
    Vanover, Kimberly E.
    Mates, Sharon
    McIntyre, Roger S.
    Tohen, Mauricio
    BIPOLAR DISORDERS, 2023, 25 (06) : 478 - 488
  • [38] SAFETY, PHARMACOKINETICS AND EARLY SIGNALS FOR EFFICACY WITH ITI-007, A NOVEL INVESTIGATIONAL NEW DRUG FOR THE TREATMENT OF SCHIZOPHRENIA AND RELATED DISORDERS
    Vanover, Kimberly E.
    Davis, R. E.
    Ereshefsky, L.
    Gertsik, L.
    Ettekal, A. E.
    Mates, S.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 325 - 325
  • [39] Lumateperone (ITI-007): a novel investigational agent with broad therapeutic potential across multiple neuropsychiatric disorders
    Vanover, K. E.
    O'Gorman, C.
    Correll, C. U.
    Glass, S.
    Mates, S.
    Saillard, J.
    Weingart, M.
    Davis, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S660 - S661
  • [40] FAVORABLE LONG-TERM SAFETY PROFILE OF LUMATEPERONE IITI-007): RESULTS FROM A 12 MONTH OPEN LABEL SAFETY STUDY FOR LUMATEPERONE IN PATIENTS WITH STABLE SYMPTOMS OF SCHIZOPHRENIA
    Vanover, Kimberly
    Satlin, Andrew
    Durgam, Saresh
    Weingart, Michal
    Saillard, Jelena
    Sanchez, Juan
    Hossain, Shawon
    Glass, Steven
    Kozauer, Susan
    Mates, Sharon
    Davis, Robert
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S351 - S351
12345